Is the insulin necessary for the struggle against oxidative stress in diabetes mellitus type 2 – a pilot study

Igor Salatić; Tamara Dragović; Ivana Stevanović; Biljana Drašković Pavlović; Milica Ninković

doi:10.2298/VSP201019138S

Igor Salatić University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
Tamara Dragović University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
Ivana Stevanović University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
Biljana Drašković Pavlović University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
Milica Ninković University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia

DOI: https://doi.org/10.2298/VSP201019138S

Keywords: diabetes mellitus, type 2, insulin, oxidative stress

Abstract

Background/Aim. Hyperglycaemia has a detrimental effect on the progress of micro/macrovascular complications in patients with diabetes mellitus type 2 (T2DM). Additionally, all known complications in T2DM are coupled with oxidative stress developed from different metabolic pathways. The aim of this study was to estimate the quality of glucoregulation and the degree of oxidative stress in T2DM patients depending on the applied therapeutic protocol and assess their correlation with clinical data and crucial biochemical parameters important for the development of diabetes complications. Methods. All included patients were divided into two groups: those treated with oral antidiabetic drugs (OAD) and those treated with oral antidiabetic drugs and insulin (OADINS). Thiobarbituric acid reactive substances (TBARS), total sulfhydryl groups (TSH), the activity of superoxide dismutase (SOD), total nitrites (NOx), vascular endothelial growth factor (VEGF), and activities of matrix metalloproteinase 9 (MMP9) were measured, together with lipid profile and routine biochemical parameters. All subjects were analyzed for demographic characteristics and detailed medical history as well as smoking habits and calculated for body mass index (BMI). Results. All patients were uniformly poor glucoregulated and dyslipidemic. SOD activity was decreased, and lipid peroxidation was increased in the OAD group compared to OADINS. Deficient glucoregulation in both the OAD and the OADINS groups did not associate with an oxidative state outcome. In both of these groups, the concentrations of VEGF and MMP9 were significantly higher than in controls. Conclusion. The better antioxidative outcome, expressed with a normalized concentration of TBARS, preserved TSH, and normalized SOD activity in T2DM patients treated with OADINS compared to those treated exclusively with OAD, suggests the need for more careful consideration of earlier insulin introduction into T2DM therapy in order to prevent the development of complications.

References

Hodish I. For debate; pharmacological priorities in advanced type 2 diabetes. J Diabetes Complications. 2020; 34(5): 107510.

Brownlee M. Biochemistry and molecular cell biology of diabet-ic complications. Nature 2001; 414(6865): 813‒20.

Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differ-ences in risk, pathophysiology and complications of type 2 di-abetes mellitus. Endocr Rev 2016; 37(3): 278‒316.

Jun JE, Jin SM, Baek J, Oh S, Hur KY, Lee MS, et al. The asso-ciation between glycemic variability and diabetic cardiovascu-lar autonomic neuropathy in patients with type 2 diabetes. Cardiovasc Diabetol 2015; 14(1): 70.

Förstermann U, Xia N, Li H. Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circ Res 2017; 120(4): 713‒35.

Škrha J, Šoupal J, Škrha J Jr, Prázný M. Glucose variability, HbA1c and microvascular complications. Rev Endocr Metab Disord 2016; 17(1): 103‒10.

Oguntibeju OO. Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links. Int J Physiol Pathophysiol Pharmacol 2019; 11(3): 45‒63.

Schnell O, Crocker JB, Weng J. Impact of HbA1c Testing at Point of Care on Diabetes Management. J Diabetes Sci Tech-nol 2017; 11(3): 611‒7.

Shen GX. Oxidative stress and diabetic cardiovascular disor-ders: roles of mitochondria and NADPH oxidase. Can J Phys-iol Pharmacol 2010; 88(3): 241‒8.

Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids 2011; 41(2): 271‒90.

Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007; 8(3): 221‒33.

Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int Suppl 2000; 77: S113‒9.

Pugliese G, Penno G, Natali A, Barutta F, Di Paolo S, Reboldi G, et al. Diabetic kidney disease: New clinical and therapeutic is-sues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”. J Nephrol 2020; 33(1): 9‒35.

Lee MY, Hsiao PJ, Huang YT, Huang JC, Hsu WH, Chen SC, et al. Greater HbA1c variability is associated with increased car-diovascular events in type 2 diabetes patients with preserved renal function, but not in moderate to advanced chronic kid-ney disease. PLoS One 2017; 12(6): e0178319.

Ellman G. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82(1): 70‒7.

Girotti MJ, Khan N, McLellan BA. Early measurement of sys-temic lipid peroxidation products in the plasma of major blunt trauma patients. J Trauma 1991; 31(1): 32‒5.

Sun M, Zigman S. An improved spectrophotometric assay for superoxide dismutase based on epinephrine autoxidation. Anal Biochem 1978; 90(1): 81‒9.

Navarro-Gonzálvez JA, García-Benayas C, Arenas J. Semiauto-mated measurement of nitrate in biological fluids. Clin Chem 1998; 44(3): 679‒81.

Giacco F, Brownlee M. Oxidative stress and diabetic complica-tions. Circ Res 2010; 107(9): 1058‒70.

Ito F, Sono Y, Ito T. Measurement and Clinical Significance of Lipid Peroxidation as a Biomarker of Oxidative Stress: Oxida-tive Stress in Diabetes, Atherosclerosis, and Chronic Inflam-mation. Antioxidants (Basel) 2019; 8(3): 72.

Vigersky R, Shrivastav M. Role of continuous glucose monitor-ing for type 2 in diabetes management and research. J Diabetes Complications 2017; 31(1): 280‒7.

Verma MK, Singh SP, Alam R, Verma P. Comparative Study on MDA, SOD and HbA1c Levels in Patients of Type 2 Dia-betes Mellitus with Retinopathy and Without Retinopathy. Int J Pharm Sci Res 2016; 7(10): 4184‒90.

Song Y, Ding W, Bei Y, Xiao Y, Tong H, Wang L, et al. Insulin is a potential antioxidant for diabetes-associated cognitive de-cline via regulating Nrf2 dependent antioxidant enzymes. Bi-omed Pharmacother 2018; 104: 474‒84.

Su J, Zhao L, Zhang X, Cai H, Huang H, Xu F, et al. HbA1c variability and diabetic peripheral neuropathy in type 2 diabet-ic patients. Cardiovasc Diabetol 2018; 17(1): 47.

Kim JM, Kim SS. Management of Hyperglycemia in Type 2 Di-abetes: A Summary of New Consensus Report from the Amer-ican Diabetes Association and the European Association for the Study of Diabetes in 2018. J Korean Diabetes 2019; 20(1): 6‒9. (Korean)

Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obe-sity and metabolic disease. J Clin Invest 2017; 127(1): 1‒4.

Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svens-son AM, et al. Risk factors, mortality, and cardiovascular out-comes in patients with type 2 diabetes. N Engl J Med 2018; 379(7): 633‒44.

Jaimes EA, DeMaster EG, Tian RX, Raij L. Stable compounds of cigarette smoke induce endothelial superoxide anion pro-duction via NADPH oxidase activation. Arterioscler Thromb Vasc Biol 2004; 24(6): 1031‒6.

Steffen Y, Vuillaume G, Stolle K, Roewer K, Lietz M, Schueller J, et al. Cigarette smoke and LDL cooperate in reducing nitric oxide bioavailability in endothelial cells via effects on both eNOS and NADPH oxidase. Nitric Oxide 2012; 27(3): 176‒84.

Liu A, Wu Q, Guo J, Ares I, Rodríguez JL, Martínez-Larrañaga MR, et al. Statins: Adverse reactions, oxidative stress and metabolic interactions. Pharmacol Ther 2019; 195: 54‒84.

Dworacka M, Krzyżagórska E, Wesołowska A, Borowska M, Is-kakova S, Dworacki G. Statins in low doses reduce VEGF and bFGF serum levels in patients with type 2 diabetes mellitus. Pharmacology 2014; 93(1‒2): 32‒8.

Husain K, Hernandez W, Ansari RA, Ferder L. Inflammation, oxidative stress and renin angiotensin system in atherosclero-sis. World J Biol Chem 2015; 6(3): 209‒17.

Chalupsky K, Cai H. Endothelial dihydrofolate reductase: criti-cal for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc Natl Acad Sci USA 2005; 102(25): 9056‒61.

Nakamura K, Murakami M, Miura D, Yunoki K, Enko K, Tanaka M, et al. Beta-blockers and oxidative stress in patients with heart failure. Pharmaceuticals (Basel) 2011; 4(8): 1088‒100.

Perez-Reyes E. Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev 2003; 83(1): 117‒61.

Preston Mason R. Pleiotropic effects of calcium channel block-ers. Curr Hypertens Rep. 2012; 14(4): 293‒303.

Kattoor AJ, Pothineni NVK, Palagiri D, Mehta JL. Oxidative Stress in Atherosclerosis. Curr Atheroscler Rep 2017; 19(11): 42.

Tousoulis D, Papageorgiou N, Androulakis E, Siasos G, Latsios G, Tentolouris K, et al. Diabetes mellitus-associated vascular impairment: novel circulating biomarkers and therapeutic approaches. J Am Coll Cardiol 2013; 62(8): 667‒76.

Domingueti CP, Dusse LM, Carvalho M, de Sousa LP, Gomes KB, Fernandes AP. Diabetes mellitus: The linkage be-tween oxidative stress, inflammation, hypercoagulability and vascular complications. J Diabetes Complications 2016; 30(4): 738‒45.